XML 48 R17.htm IDEA: XBRL DOCUMENT
v3.19.3

LEASES | 6 Months Ended
--- | ---
Sep. 28, 2019
Leases [Abstract] |
LEASES | 11. LEASES Lessee Activity The Company has operating leases for office space, land, warehouse and manufacturing space, R&D laboratories, vehicles and certain equipment. Finance leases are not significant. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of 1 year to approximately 30 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to the Company's adoption of ASC 842, the Company measured the lease liabilities and right-of-use assets using the incremental borrowing rate as of March 31, 2019. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The following table presents supplemental balance sheet information related to the Company's operating leases:
(In thousands) |  | September 28, 2019
Assets |  |
Operating lease right-of-use assets in Other long-term assets |  | $ | 19,356 |
Liabilities |  |
Operating lease liabilities in Other current liabilities |  | $ | 4,966 |
Operating lease liabilities in Other long-term liabilities |  | $ | 14,051 |
The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
|  | September 28, 2019
Weighted average remaining lease term |  | 4.8 Years |
Weighted average discount rate |  | 5.27 | %
During the three and six months ended September 28, 2019 the Company's operating lease cost was $2.1 million and $4.6 million, respectively. The following table presents supplemental cash flow information related to our operating leases:
(In thousands) |  | Three Months Ended September 28, 2019 |  | Six Months Ended September 28, 2019
Cash paid for amounts included in the measurement of operating lease liabilities |  |  |  |
Operating cash flows used for operating leases |  | $ | 1,783 |  |  | $ | 3,834 |
The following table presents the maturities of our operating lease liabilities as of September 28, 2019:
Fiscal Year (In thousands) |  | Operating Leases
2020 (excluding the first half of 2020) |  | $ | 3,003 |
2021 |  | 5,746 |
2022 |  | 4,210 |
2023 |  | 3,284 |
2024 |  | 1,853 |
Thereafter |  | 3,534 |
Total future minimum operating lease payments |  | 21,630 |
Less: imputed interest |  | (2,613 | )
Present value of operating lease liabilities |  | $ | 19,017 |
As of September 28, 2019, the Company has an additional lease for office space of $98.6 million and has a lease term, including renewal options, of up to 22 years. The Company will take control of the facility upon lease commencement during third quarter of fiscal 2020. Lessor Activity Assets on the Company's balance sheet classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represents less than 3 percent of the Company's total net sales.

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=77888251 + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration